University of Washington biotech start-up to develop game-changing cancer therapies

(UW Center for Commercialization (UW C4C)) Taiwan-based BRIM (Beyond Research and Innovative Medicines) Biotechnology has entered into an agreement with UW biotech start-up Compliment Corporation to develop Compliment's two oncology platform technologies based on the research of André Lieber, UW professor of medicine. Both technologies incorporate recombinant proteins aimed at improving efficacy and decreasing toxicity of current and new cancer therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

In this report, we are adding an extra finding, in which we show that the levels of circulating NRP-1 were significantly increased in patients who received NAC and had a partial response. Assessing patients who underwent NAC indicated that the levels of NRP-1 measured post-NAC were significantly higher in younger patients and patients with either a low or a medium body mass index (BMI), as well as in patients who remained with larger tumor size and partial response. Previously, we showed that SNAI1 expression in the immune cells collected from the peripheral blood of breast cancer patients was significantly higher in patie...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: 23 April 2019Source: Cell Reports, Volume 27, Issue 4Author(s): Erin E. Mulkearns-Hubert, Luke A. Torre-Healy, Daniel J. Silver, Jennifer T. Eurich, Defne Bayik, Emily Serbinowski, Masahiro Hitomi, John Zhou, Bartlomiej Przychodzen, Renliang Zhang, Samuel A. Sprowls, James S. Hale, Tyler J. Alban, Artem Berezovsky, Brent A. Bell, Paul R. Lockman, Babal K. Jha, Justin D. LathiaSummaryGap-junction-mediated cell-cell communication enables tumor cells to synchronize complex processes. We previously found that glioblastoma cancer stem cells (CSCs) express higher levels of the gap junction protein Cx46 compared...
Source: Cell Reports - Category: Cytology Source Type: research
Discussion: The data reviewed here show successful treatment on biologics despite concurrent malignancy, though confirmatory research is needed. J Drugs Dermatol. 2019;18(4):387-390. PMID: 31013012 [PubMed - as supplied by publisher]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.9b03519
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
Publication date: September 2019Source: Materials Science and Engineering: C, Volume 102Author(s): Pankaj Dwivedi, Shuya Han, Farhana Mangrio, Rong Fan, Monika Dwivedi, Zhiqiang Zhu, Fangsheng Huang, Qiang Wu, Renuka Khatik, David E. Cohn, Ting Si, Shuiying Hu, Alex Sparreboom, Ronald X. XuAbstractOvarian cancer is one of the most lethal gynecologic malignancies due to its rapid proliferation, frequent acquisition of chemoresistance, and widespread metastasis within the peritoneal cavity. Intraperitoneal (IP) chemotherapy has demonstrated significant anti-cancer potential but its broad clinical application is hindered by s...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
The ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase 1 (CHK1) pathway plays an essential role in suppressing replication stress from DNA damage and oncogene activation.
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Review Source Type: research
The U.S. Food and Drug Administration has approved Merck&Co Inc's cancer therapy Keytruda (pembrolizumab) as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Yi-Cheng Gao, Xiong-Hui Zhou* and Wen Zhang* Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, China Due to the high heterogeneity and complexity of cancer, it is still a challenge to predict the prognosis of cancer patients. In this work, we used a clustering algorithm to divide patients into different subtypes in order to reduce the heterogeneity of the cancer patients in each subtype. Based on the hypothesis that the gene co-expression network may reveal relationships among genes, some communities in the network could influence the prognosis o...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusions: This study demonstrated a rapid improvement of many symptoms in the subacute post-operative period in pituitary tumor patients. Disturbed sleep was identified as the only symptom to worsen post-operatively, encouraging potential prospective interventions to improve sleep, and subsequently improve the QOL in pituitary tumor patients following surgical intervention. Introduction Pituitary tumors are relatively rare primary central nervous system (CNS) tumors in adults (1) but make up 10% of all neurosurgical interventions in the United States (2). They are often an incidental finding in autopsies and brain...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Toxicology | University of Washington